CD44 and cancer: Another study showed that early intervention with a Syndecan-1 inhibitor (OGT2115) or RNAi-mediated Syndecan-1 silencing in a transgenic mouse model of prostate cancer reduced the incidence of adenocarcinoma and the number of c-kit(+)/CD44(+) cells in cancer foci [43].